Androgen Receptor Expression in Triple-Negative Breast Cancer
Background: Triple-negative breast cancer (TNBC) accounts for 15 to 20% of all breast cancers. These patients do not benefit from hormone therapy and other targeted treatments of breast cancer. Recently, researchers proposed the use of androgen receptor (AR)-targeted therapies in this subset of pati...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kaviani Breast Disease Institute
2019-05-01
|
| Series: | Archives of Breast Cancer |
| Subjects: | |
| Online Access: | https://archbreastcancer.com/index.php/abc/article/view/249 |
| _version_ | 1818532365163560960 |
|---|---|
| author | Samane Jam Alireza Abdollahi Sanaz Zand Zahra Khazaeipour Ramesh Omranipour Massoome Najafi |
| author_facet | Samane Jam Alireza Abdollahi Sanaz Zand Zahra Khazaeipour Ramesh Omranipour Massoome Najafi |
| author_sort | Samane Jam |
| collection | DOAJ |
| description | Background: Triple-negative breast cancer (TNBC) accounts for 15 to 20% of all breast cancers. These patients do not benefit from hormone therapy and other targeted treatments of breast cancer. Recently, researchers proposed the use of androgen receptor (AR)-targeted therapies in this subset of patients. The rate of AR expression in TNBC patients varies from 0 to 53%. AR positivity is associated with a better outcome for breast cancer patients. The purpose of this study was to evaluate AR status in TNBC patients and its association with other demographic and pathologic features.
Methods: This cross-sectional study was conducted in the Cancer Institute of Iran, affiliated with Tehran University of Medical Sciences, in 2015. Archived formalin-fixed, paraffin-embedded breast tumor blocks were evaluated to determine the AR status of the tumors. Demographic and pathologic characteristics of the patients were retrieved from the department of pathology database. Data were analyzed with SPSS 18.0.
Results: Seventy-seven TNBC patients with the mean age of 45.3?±?11.5 were assessed. Twenty-six patients (34%) showed AR expression, and 51 patients (56%) did not have AR expression. There was no significant correlation between AR status and age, tumor size, histopathologic type of tumor, or lymph node involvement. However, AR positivity had a statistically significant association with a lower tumor grade and lymphovascular invasion (P?=?0.029 and P?=?0.01, respectively).
Conclusion: TNBC patients with AR expression tend to have lower tumor grades and higher rates of lymphovascular invasion. |
| first_indexed | 2024-12-11T17:44:33Z |
| format | Article |
| id | doaj.art-3e33f27b1a294b99a71366ec3714fd3b |
| institution | Directory Open Access Journal |
| issn | 2383-0433 |
| language | English |
| last_indexed | 2024-12-11T17:44:33Z |
| publishDate | 2019-05-01 |
| publisher | Kaviani Breast Disease Institute |
| record_format | Article |
| series | Archives of Breast Cancer |
| spelling | doaj.art-3e33f27b1a294b99a71366ec3714fd3b2022-12-22T00:56:25ZengKaviani Breast Disease InstituteArchives of Breast Cancer2383-04332019-05-0110.32768/abc.20196292-95Androgen Receptor Expression in Triple-Negative Breast CancerSamane Jam0Alireza Abdollahi1Sanaz Zand2Zahra Khazaeipour3Ramesh Omranipour4Massoome Najafi5Department of Surgery, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Pathology, Tehran University of Medical Sciences, Tehran, IranDepartment of Research, Kaviani Breast Disease Institute, Tehran, IranBrain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, IranDepartment of Surgery, Tehran University Medical Sciences, Tehran, Iran AND Breast Cancer Research Center, Tehran University Medical Sciences, Tehran, IranDepartment of Surgery, Tehran University of Medical Sciences, Tehran, IranBackground: Triple-negative breast cancer (TNBC) accounts for 15 to 20% of all breast cancers. These patients do not benefit from hormone therapy and other targeted treatments of breast cancer. Recently, researchers proposed the use of androgen receptor (AR)-targeted therapies in this subset of patients. The rate of AR expression in TNBC patients varies from 0 to 53%. AR positivity is associated with a better outcome for breast cancer patients. The purpose of this study was to evaluate AR status in TNBC patients and its association with other demographic and pathologic features. Methods: This cross-sectional study was conducted in the Cancer Institute of Iran, affiliated with Tehran University of Medical Sciences, in 2015. Archived formalin-fixed, paraffin-embedded breast tumor blocks were evaluated to determine the AR status of the tumors. Demographic and pathologic characteristics of the patients were retrieved from the department of pathology database. Data were analyzed with SPSS 18.0. Results: Seventy-seven TNBC patients with the mean age of 45.3?±?11.5 were assessed. Twenty-six patients (34%) showed AR expression, and 51 patients (56%) did not have AR expression. There was no significant correlation between AR status and age, tumor size, histopathologic type of tumor, or lymph node involvement. However, AR positivity had a statistically significant association with a lower tumor grade and lymphovascular invasion (P?=?0.029 and P?=?0.01, respectively). Conclusion: TNBC patients with AR expression tend to have lower tumor grades and higher rates of lymphovascular invasion.https://archbreastcancer.com/index.php/abc/article/view/249Triple Negative breast cancer (TNBC)Androgen receptor (AR)Histopathological features |
| spellingShingle | Samane Jam Alireza Abdollahi Sanaz Zand Zahra Khazaeipour Ramesh Omranipour Massoome Najafi Androgen Receptor Expression in Triple-Negative Breast Cancer Archives of Breast Cancer Triple Negative breast cancer (TNBC) Androgen receptor (AR) Histopathological features |
| title | Androgen Receptor Expression in Triple-Negative Breast Cancer |
| title_full | Androgen Receptor Expression in Triple-Negative Breast Cancer |
| title_fullStr | Androgen Receptor Expression in Triple-Negative Breast Cancer |
| title_full_unstemmed | Androgen Receptor Expression in Triple-Negative Breast Cancer |
| title_short | Androgen Receptor Expression in Triple-Negative Breast Cancer |
| title_sort | androgen receptor expression in triple negative breast cancer |
| topic | Triple Negative breast cancer (TNBC) Androgen receptor (AR) Histopathological features |
| url | https://archbreastcancer.com/index.php/abc/article/view/249 |
| work_keys_str_mv | AT samanejam androgenreceptorexpressionintriplenegativebreastcancer AT alirezaabdollahi androgenreceptorexpressionintriplenegativebreastcancer AT sanazzand androgenreceptorexpressionintriplenegativebreastcancer AT zahrakhazaeipour androgenreceptorexpressionintriplenegativebreastcancer AT rameshomranipour androgenreceptorexpressionintriplenegativebreastcancer AT massoomenajafi androgenreceptorexpressionintriplenegativebreastcancer |